When the quarter's footnotes do the talking

Revenue for the half year fell 12.0% to ¥12,542 million, but the group posted ¥1,363 million of operating profit, largely from crowdfunding rather than property sales. It still recorded a ¥1,056 million net loss and an equity ratio of 1.9%, while the auditor declined to express a conclusion on the half-year statements as the company investigates Yamawake Estate transactions with buyback arrangements.

First-quarter sales rose 6.6% to ¥1,010 million, but operating loss widened to ¥434 million as the group pushed deeper into defense, UTM and overseas build-out. It kept full-year guidance unchanged, formed an Estonia defense hub and set out a staged warrant financing plan with estimated net proceeds of about ¥14.5 billion.

The three months to April 30 produced no revenue and an ¥836 million net loss, yet AKUGO was added to Japan's reimbursement list in May at ¥72 million and commercial sales began. SanBio also said it agreed Phase 3 trial design with the FDA for traumatic brain injury, though the company did not disclose early sales volume or hospital uptake.

The company raised revenue guidance to ¥6,950 million from ¥6,620 million and business profit to ¥820 million from ¥560 million on stronger electronics orders and smooth production. But the larger jump in profit attributable to owners, to ¥1,835 million from ¥730 million, also reflects April-end valuation gains on a Singapore-listed holding that will be remeasured each quarter.

Full-year revenue guidance rose by just ¥8 million to ¥3,501 million, while operating profit was lifted to ¥822 million and ordinary profit to ¥927 million as tripla Book volume and take rate stayed on plan, costs came down and cash from advance payments earned more interest. Management says the rest-of-year assumptions on interest income and foreign exchange remain conservative.

After sales of ¥10,828 million and operating profit of ¥1,088 million beat the company's prior forecast, the board authorized repurchases of up to 50,000 shares, or 3.84% of shares outstanding excluding treasury stock, with a ¥400 million cap. Next year's guide drops back to ¥720 million of operating profit, which makes the buyback read more like balance-sheet confidence than exuberance.

After agreeing to buy GMO Digital Lab for ¥700 million, plus a potential earn-out of up to ¥100 million, the company moved its dividend rule to consolidated accounts and nudged its year-end payout forecast to ¥50.56 from ¥48.24. The revised group outlook adds far more revenue than net profit, because a matching ¥700 million bank loan helps fund the deal and drags interest costs into the picture.

JTM says it holds 55,211,107 RISE shares and equivalents, or 53.99% of the total, after the tender offer closed, replacing the former parent and pushing RISE into controlled-subsidiary territory. The stake includes 6,244,307 Class A preferred shares that JTM wants converted into common stock, while its side agreement stops short of seeking a board majority for at least three years.

The group will unwind its alliance with Antway and prepare to transfer the house-meal business at Kushikatsu Tanaka, a unit that generated ¥1,302,610 thousand of sales in the year to November 2025, or 6.2% of consolidated revenue. A separate ¥500 million Mizuho loan earmarked for new directly operated stores makes the capital-allocation message clear enough even before the transfer price and transferee details are disclosed.

The hotel REIT reported a distribution of ¥6,832 per unit for the period ended April 30, ¥332 above its earlier forecast, as variable rent from roadside assets and the five the b hotels ran ahead of assumptions. Guidance slips to ¥6,700 for the next period before recovering to ¥6,850, with higher rates, repairs and a cooler Osaka market after Expo strength offsetting new lease terms at three Comfort hotels.

Revenue for the half year ended April rose 15.3% to ¥22.35 billion and total DPU reached ¥3,407, but guidance falls to ¥1,908 next period because the latest payout included much larger excess distributions and reserve add-backs. Management's recurring EPU still edges higher and the REIT is adding Prime Maison Kinshicho for ¥4.27 billion, so the awkward-looking headline says more about mix than occupancy panic.

First-half revenue rose 17.5% to ¥2,989 million and operating profit more than doubled to ¥52 million, helped by steady IT-services demand and NEX's first-half IoT contribution. The Zenko acquisition has so far changed the balance sheet faster than earnings, though: goodwill stood at ¥2,289 million after a ¥207 million impairment, while Zenko's profit and loss only starts flowing through from the third quarter and full-year guidance stayed unchanged.